INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Hold” from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has received an average recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.00.

A number of research firms recently commented on INMB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INmune Bio in a research report on Wednesday, October 8th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Sunday, December 14th.

Hedge Funds Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. Focus Partners Advisor Solutions LLC lifted its stake in shares of INmune Bio by 321.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock valued at $113,000 after acquiring an additional 37,224 shares during the last quarter. PFG Investments LLC bought a new stake in INmune Bio during the 2nd quarter worth $27,000. PNC Financial Services Group Inc. acquired a new position in INmune Bio in the 2nd quarter worth about $87,000. Jane Street Group LLC bought a new position in INmune Bio in the first quarter valued at about $142,000. Finally, Modera Wealth Management LLC acquired a new stake in shares of INmune Bio during the second quarter valued at about $36,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Price Performance

Shares of NASDAQ INMB opened at $1.73 on Friday. The firm has a market cap of $45.98 million, a price-to-earnings ratio of -0.82 and a beta of 0.70. The stock’s fifty day moving average price is $1.68 and its two-hundred day moving average price is $2.00. INmune Bio has a one year low of $1.38 and a one year high of $11.64.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.07. On average, equities analysts anticipate that INmune Bio will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.